Table 2.
Baseline characteristics LiraFlame26
| Total | Liraglutide | Placebo | P-value | |
|---|---|---|---|---|
| n | 102 | 51 | 51 | |
| Age (years) | 66.4 (8.2) | 65.9 (8.6) | 66.9 (7.8) | 0.556 |
| Women | 16 (15.7%) | 6 (11.8%) | 10 (19.6%) | 0.414 |
| Weight (kg) | 91.2 (17.3) | 94.5 (19.9) | 87.9 (13.6) | 0.055 |
| Diabetes duration (years) | 13 (8.7) | 13.3 (9.1) | 12.6 (8.3) | 0.657 |
| HbA1c (mmol/mol) | 58.4 (10.1) | 58.7 (9.6) | 58 (10.6) | 0.725 |
| HbA1c (%) | 7.5 (0.9) | 7.5 (0.9) | 7.5 (1) | 0.725 |
| Total cholesterol (mmol/L) | 4.1 (0.8) | 4.1 (0.8) | 4.1 (0.8) | 0.855 |
| LDL (mmol/L) | 2.10 (0.67) | 2.05 (0.72) | 2.15 (0.62) | 0.476 |
| Triglyceride (mmol/L) | 1.81 (1.03) | 2.07 (1.19) | 1.56 (0.78) | 0.013 |
| Systolic blood pressure (mm Hg) | 135 (17) | 133 (14) | 137 (20) | 0.253 |
| eGFR (mL/min/1.73m2) | 83 (16) | 83 (18) | 84 (15) | 0.746 |
| UAER (mg/d) | 2 [2-3] | 3 [2-4] | 2 [2-3] | 0.201 |
Mean (SD), n (%) or median [IQR], groupwise comparison between liraglutide and placebo was carried out using chi square test for categorical variables and ANOVA for continuous variables
LDL Low-density lipoprotein, Egfr Estimated glomerular filtration rate, UAER Urinary albumin excretion rate